Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Inclusion Criteria: * Histologically confirmed locally advanced adenocarcinoma of the prostate, graded: T3 or T4 or pT3 on biopsies (presence of tumour tissue in periprostatic fat observed on biopsies), N0 (absence of metastatic), M0 (no distant metastases detectable on the following examinations: bone scan, chest x-ray, abdominal and pelvic ultrasound). * Patient in whom the prostatic adenocarcinoma has received no prior treatment of any type, with the possible exception of transurethral resection due to obstructive symptoms. * Patient with a Karnofsky index greater than or equal to (≥) 70. * Patient aged under 80 years on the randomization date. * Patient with a life expectancy of at least 7 years. * Patient who, after having received clear information, gave his written consent to participate and cooperate in the study. * Patient for whom a recent blood test (less than \[\<\] 2 months) has not revealed elevated transaminases ≥ 3 times the normal laboratory range. Exclusion Criteria: * Patient incapable of understanding the information supplied concerning the study or of giving his consent, or having refused to sign the informed consent form, * Patient for whom there is a risk that follow-up in compliance with the conditions stipulated by the protocol will not be possible, * Patient having already received prior treatment for prostate cancer, excluding transurethral resection of the prostate to relieve obstruction, * Patient having undergone surgical castration, or with a history of bilateral adrenalectomy or hypophysectomy, * Patient having had another cancer within the previous 5 years (including carcinoma in situ of the bladder) excluding basocellular epithelioma or carcinoma in situ (other than in the bladder), * Patient with lymph node or metastatic spread of the prostatic adenocarcinoma suspected on imaging, * Patient with a non-controlled severe active disease, * Patient with a contraindication to external prostatic radiotherapy, * Patient receiving or having received another experimental treatment within 3 months prior to inclusion in the study, * Patient with impaired liver function or elevated transaminases ≥3 times the normal laboratory range.